STOCK TITAN

FDA Clears MiniMed Fit™ -- World's First and Only Tubeless Insulin Pump with Up to Seven-Day Wear and Zero Interruptions

(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

MiniMed (Nasdaq: MMED) received FDA clearance for MiniMed Fit, its first tubeless insulin pump, for people with diabetes ages 7 and older.

The clearance covers Type 1 and Type 2 diabetes. The pump offers up to seven days of wear and a 300-unit insulin capacity, with app control and SmartGuard automated insulin delivery. Seven-day wear requires a total daily insulin dose of less than 42 units; daily dosage may affect replacement frequency.

MiniMed expects a phased U.S. rollout in spring 2027, following an early customer experience phase expected in its fourth quarter of fiscal 2027. Access will be through pharmacies. The company has been building manufacturing capacity and commercial infrastructure and plans further capacity expansion as commercialization progresses. It also plans integration with its next-generation fully closed-loop technology, which remains investigational.

Loading...
Loading translation...
4 points · 1 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

0 major · 1 point

Hollow bars mark forward-looking points. How the balance works

Positive

  • Major pointFDA clearance adds MiniMed's first tubeless pump for Type 1 and Type 2 diabetes, ages 7 and older.
  • Moderate point. Forward-looking: it has not happened yet and may not happen.Phased U.S. rollout is expected in spring 2027, following an early experience phase expected in fiscal Q4 2027.
  • Minor point. Forward-looking: it has not happened yet and may not happen.Manufacturing capacity and commercial infrastructure have been under development; MiniMed plans further manufacturing expansion as commercialization progresses.
  • Minor point. Forward-looking: it has not happened yet and may not happen.Future integration with MiniMed's next-generation fully closed-loop technology is planned; that technology remains investigational.

Negative

  • Minor pointSeven-day wear requires less than 42 units of total daily insulin; dosage may affect replacement frequency.

Key Figures

Pump wear: Up to seven days Insulin capacity: 300 units Instinct sensor wear: Up to 15 days +5 more
Pump wear
Up to seven days
MiniMed Fit
Insulin capacity
300 units
MiniMed Fit pump
Instinct sensor wear
Up to 15 days
Abbott sensor option at commercial launch
Time in Range
Up to 80%
Real-world SmartGuard users with recommended settings
Overnight Time in Range
91%
Real-world SmartGuard users with recommended settings
Phased U.S. rollout
Expected to begin in spring 2027
MiniMed Fit launch
Early customer experience phase
Expected to begin in fiscal year 2027 fourth quarter
Ahead of the phased U.S. rollout
Cleared age eligibility
Ages 7 and older
People with Type 1 and Type 2 diabetes

Previous Fda approval Reports

1 past event · Latest: Mar 18
Same Type 1 event
  1. Mar 18

    FDA clearance

    24h Move
    -0.2%

    Earlier clearance established SmartGuard and 300-unit pump features; this clearance adds a tubeless design.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

automated insulin delivery, closed-loop technology, real-world evidence, fda clearance
4 terms
automated insulin delivery medical
"bringing its advanced automated insulin delivery technology to a tubeless design"
A system that links a glucose sensor, an insulin pump, and control software so insulin is adjusted automatically to keep blood sugar near a target range, similar to a smart thermostat that regulates room temperature. It matters to investors because it replaces manual dosing with continuous, data-driven care, which can drive device sales, recurring subscription software services, better health outcomes, and regulatory interest—factors that affect market growth and company valuation.
closed-loop technology technical
"planned integration with MiniMed's next-generation fully closed-loop technology"
A system that measures a variable, compares that measurement to a target, and automatically adjusts outputs using feedback so the variable stays near the target without human intervention. Closed-loop technology pairs sensors, control logic (usually software or an algorithm) and actuators to create a continuous loop of sensing and correction; it is contrasted with open-loop systems that run pre-set actions without using real-time feedback. Its performance depends on sensor accuracy and the control algorithm, and because it makes automatic decisions it is often subject to specific safety and regulatory scrutiny in regulated industries like healthcare.
real-world evidence medical
"Real-world evidence."
Real-world evidence is information gathered from everyday sources like patient records, insurance claims, or everyday experiences, rather than controlled experiments or clinical trials. It helps investors understand how products or policies perform in real life, providing a more complete picture of their effectiveness and value beyond official tests. This type of evidence can influence decision-making by offering insights based on actual, everyday outcomes.
fda clearance regulatory
"announced U.S. Food and Drug Administration (FDA) clearance of MiniMed Fit"
FDA clearance is the U.S. Food and Drug Administration’s official permission to market certain medical devices or diagnostic tests after reviewing evidence that they are as safe and effective as similar products already on the market. For investors, it’s like a product passing a required safety inspection — it reduces regulatory uncertainty, speeds commercial rollout, and can directly affect sales prospects, valuation, and partnership opportunities.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

The only tubeless pump with no charging or cartridge changes for up to seven days, combined with a 300-unit insulin capacity and advanced insulin automation

NORTHRIDGE, Calif., Nov. 16, 2026 /PRNewswire/ -- MiniMed (Nasdaq: MMED) today announced U.S. Food and Drug Administration (FDA) clearance of MiniMed Fit™, the company's first tubeless insulin pump, offering people with diabetes a new differentiated option that combines up to seven days of wear, a 300-unit insulin capacity, app control and proven SmartGuard™ technology.

MiniMed Fit: Everything a tubeless pump should be.

MiniMed Fit™ marks a significant expansion of the company's insulin delivery portfolio, bringing its advanced automated insulin delivery technology to a tubeless design for the first time. With up to twice the wear time of other tubeless options* and 50% more insulin capacity,† the system reduces the number of pump changes and daily decisions, so there is less to do and less to think about with diabetes management.

"People with diabetes shouldn't have to choose between the freedom of tubeless wear and the health outcomes they deserve," said Que Dallara, chief executive officer of MiniMed. "MiniMed Fit™ brings the technology people trust from MiniMed into a tubeless design that fits their lives. Clearing FDA ahead of schedule is more proof we're executing our strategy. It puts MiniMed Fit in U.S. customers' hands sooner, and the pharmacy channel makes it easier to get."

Everything a tubeless pump should be

MiniMed Fit™ is designed to automate more of the work of diabetes management and reduce interruptions in daily routines. It combines a discreet, waterproof tubeless pump with app control on compatible iOS and Android devices and at commercial launch will offer the choice of two all-in-one sensors: Simplera Sync™ with up to seven days of wear and Instinct™, made by Abbott, with up to 15 days of wear.

  • Fewer changes. More freedom. With up to seven days of wear and 300-unit insulin capacity, MiniMed Fit™ offers up to twice the wear time and more insulin than other tubeless insulin pump options, meaning fewer pump changes and more time to focus on what matters. *†‡
  • Automation every five minutes. Powered by SmartGuard™ technology, the system automatically adjusts insulin delivery and can deliver correction doses every five minutes.§ 
  • Easier mealtimes. With Meal Detection™ technology, the system can deliver additional insulin when a meal dose is sometimes missed or underestimated. §‖
  • More time in range, day and night. Real-world users of SmartGuard™ technology have achieved up to 80% Time in Range and 91% overnight Time in Range with recommended settings, helping people spend more time in their target glucose range.  #**1,2
  • Flexible wear locations and insulin compatibility. Wear locations are back of arm, lower back, upper buttocks, abdomen, and thigh. Compatible insulins are Humalog, NovoLog, and Admelog.
  • Easier access through the pharmacy. MiniMed Fit™ will be available through the pharmacy channel, offering a convenient way for people to access.
  • Built for what's next. MiniMed Fit™ is designed for future innovation, including the planned integration with MiniMed's next-generation fully closed-loop technology (investigational).

The MiniMed Fit™ launch is expected to begin with a phased rollout in the U.S. in spring 2027, following an early customer experience phase expected to begin in MiniMed's fourth quarter of fiscal year 2027.

In preparation for launch, MiniMed has been building manufacturing capacity and commercial infrastructure alongside the regulatory process. The company plans to significantly expand manufacturing capacity as commercialization progresses to support growing demand and capitalize on a new growth opportunity in tubeless insulin pumps.

MiniMed Fit™ is cleared for people with Type 1 and Type 2 diabetes ages 7 and older. People interested in learning more about MiniMed Fit™ availability can request to receive updates at minimed.com/fit.

About MiniMed 
MiniMed is a global leader in insulin delivery, constantly advancing therapies that support people with diabetes in 80 countries. Our full-stack, integrated ecosystem, including our insulin delivery systems, CGMs, algorithms, and easy-to-use app experience, is designed to work seamlessly together, supported by white-glove, wrap-around service. For over 40 years, we've pioneered therapies people can rely on by anticipating needs, reducing burden, and helping make life with diabetes easier. Our mission is to make every day a better day for people with diabetes. 

Any forward-looking statements are subject to risks and uncertainties such as those described in MiniMed's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results. 

Footnotes & References

*Tandem Mobi can be worn up to 7 days with a required cartridge change at 3 days. Omnipod can be worn up to 3 days. Mint has 3-day wear, plus a 12-hour grace period for insulin delivery. See user guides for more details.

† Omnipod, Mint, and Mobi tubeless devices hold 200 units. See product IFUs for details.

‡ 7-day wear achievable with less than 42 units of total daily dose. Total daily dose may impact frequency of changes.

§ Refers to SmartGuard™ feature. Individual results may vary.

‖ Taking a bolus 15–20 minutes before a meal helps to keep blood sugar levels under control after eating.

¶ Due to inherent real-world data limitations, caution is advised when attempting to extrapolate these results to new patients. There could be significant differences.

# Real-world evidence. N=101,629. 86.3% users achieved >70% Time in Range

** Overnight period: 12:00 AM- 6:00 AM. Number of users with ≥10 days of sensor glucose data; Optimal settings are glucose target at 100 mg/dL (5.5 mmol/L) and Active Insulin Time (AIT) at 2 hours and used >95% of the time.

∞ Pump is waterproof up to 8 feet (2.4 meters) for 1 hour and 45 minutes. If you choose to stay connected while in water, CGM readings may not be transmitted to the pump.

1. Choudhary P, et al. Celebrating the Data from 100,000 Real-World Users of the MiniMed™ 780G System in Europe, Middle East, and Africa Collected Over 3 Years: From Data to Clinical Evidence. Diabetes Technol Ther. 2024;26 (Suppl. 3):S32-S37.15

2. McVean JJF, Niu F, Liu M, et al. Automated insulin delivery with the MiniMed™ 780G system reduces burden by improving sleep and glycaemic control overnight. Diabetes Obes Metab. 2026;28(3):2456-2460. doi:10.1111/dom.70380

 

MiniMed Fit: Everything a tubeless pump should be.

MiniMed Fit: Everything a tubeless pump should be.

MiniMed Fit: Everything a tubeless pump should be.

MiniMed Fit: Everything a tubeless pump should be.

MiniMed logo

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/fda-clears-minimed-fit--worlds-first-and-only-tubeless-insulin-pump-with-up-to-seven-day-wear-and-zero-interruptions-302940510.html

SOURCE MiniMed

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

Who is eligible for MiniMed Fit following FDA clearance?

MiniMed Fit is cleared for people with Type 1 and Type 2 diabetes ages 7 and older. It is MiniMed's first tubeless insulin pump.

When will MiniMed Fit launch in the United States?

MiniMed expects a phased U.S. rollout in spring 2027, following an early customer experience phase expected to begin in its fourth quarter of fiscal year 2027. The pump will be available through the pharmacy channel.

Which glucose sensors will MiniMed Fit offer at commercial launch?

At commercial launch, MiniMed Fit will offer a choice of Simplera Sync, with up to seven days of wear, or Instinct, made by Abbott, with up to 15 days of wear.

Keep reading